{"product_id":"do-decision-aids-actually-help-cancer-patients-decide-what-30-studies-and-4-303-patients-show","title":"Do Decision Aids Actually Help Cancer Patients Decide? What 30 Studies and 4,303 Patients Show","description":"\u003cp\u003eThis systematic review and meta-analysis pooled 30 randomized controlled trials involving 4,303 cancer patients to test whether decision aids (structured tools that explain treatment options) improve how patients make cancer treatment decisions. The researchers found that decision aids clearly improved patients' decision knowledge. This was a large effect, with a standardized mean difference of 0.91. Decision aids also modestly reduced decision conflict, the distressing uncertainty patients feel when facing hard choices. The standardized mean difference for decision conflict was −0.23. However, decision aids did not significantly improve decision satisfaction (standardized mean difference 0.03, with a confidence interval crossing zero). Web-based and mixed-format decision aids performed best, reducing both knowledge gaps and conflict, while brochure-only aids improved knowledge but not conflict.\u003c\/p\u003e\n\n\u003ch1\u003eEffects of Decision Aids on Decision Knowledge, Conflict, and Satisfaction Among Patients With Cancer: A Systematic Review and Meta-Analysis.\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Cancer Treatment Decisions Are So Difficult\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#decision-aids\"\u003eWhat Exactly Is a Decision Aid?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Researchers Conducted the Study\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-characteristics\"\u003eWhat the 30 Included Studies Looked Like\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#measurement\"\u003eHow the Researchers Measured Results\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#findings\"\u003eMain Findings: Knowledge Up, Conflict Down, Satisfaction Unchanged\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#subgroups\"\u003eSubgroup Findings: Which Formats Work Best\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#bias\"\u003eRisk of Bias and Certainty of the Evidence\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#nursing\"\u003eWhat This Means for Nurses and Health Systems\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003ePractical Recommendations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn 30 randomized trials with 4,303 cancer patients, decision aids clearly improved decision knowledge, a large effect, with low certainty of evidence.\u003c\/li\u003e\n\u003cli\u003eThe same trials found decision aids modestly reduced decision conflict, the distressing uncertainty of hard choices, with moderate certainty of evidence.\u003c\/li\u003e\n\u003cli\u003eDecision aids did not significantly improve decision satisfaction; the result was imprecise and crossed zero, so no clear answer either way.\u003c\/li\u003e\n\u003cli\u003eIn exploratory subgroup analyses, only web-based and mixed formats, and aids tailored to one specific cancer type, reduced decision conflict.\u003c\/li\u003e\n\u003cli\u003eDecision aids should be used alongside, not instead of, a conversation with your care team, and tailored to cancer type, education, and health literacy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Cancer Treatment Decisions Are So Difficult\u003c\/h2\u003e\n\n\u003cp\u003eMore people are being diagnosed with cancer than ever before. This is partly good news: better diagnostic technology and more treatment options mean the disease is detected more often and treated in more ways. But those same advances create a new problem — the decisions themselves have become harder to make. Cancer care is now \"preference-sensitive,\" meaning there is often no single obviously correct choice.\u003c\/p\u003e\n\n\u003cp\u003ePatients must weigh complicated clinical information. This includes details such as disease stage, tumor size, and tumor location. They must also weigh their own personal circumstances. Educational level, health literacy (the ability to understand and use health information), socioeconomic status, personal values, and preferences all shape which treatment feels right.\u003c\/p\u003e\n\n\u003cp\u003eOn top of that, cancer decisions involve high-stakes trade-offs between survival and quality of life. Treatment options evolve rapidly. The emotional weight of a cancer diagnosis makes these conversations even harder. All of this can overwhelm patients and complicate shared decision-making (SDM — a process in which clinicians and patients make medical decisions together, based on the patient's values).\u003c\/p\u003e\n\n\u003cp\u003eFor nurses, a key challenge is conveying information clearly within limited time. Decision knowledge — a patient's objective understanding of their disease and treatment options — is one of the most important factors driving the choices people make. The main way patients gain that knowledge is by asking their healthcare providers questions. Yet patients face real barriers to asking. They may fear negative reactions, feel confused by medical terminology, or believe that nurses and doctors are simply \"too busy.\"\u003c\/p\u003e\n\n\u003cp\u003eWhen information is missing, a second problem often appears: decision conflict. Researchers define decision conflict as a state of uncertainty about which course of action to choose when the options involve risks, losses, or challenges to personal values. Decision conflict typically comes from three sources. The first is a lack of clear information about the options and their likely benefits and harms. The second is uncertainty about one's own values and preferences. The third is perceived insufficient support or guidance during the decision.\u003c\/p\u003e\n\n\u003cp\u003eDecision satisfaction is a third important measure. It captures how content a patient feels with the decision or the decision process itself, and it reflects both the quality of the decision and the patient's experience. Past research shows that cancer patients who rely only on their own abilities often feel dissatisfied with the decisions they make and the results they get. They report not having enough knowledge at the time, not being clear about their own values, and having unaddressed concerns. When cancer patients lack decision knowledge, they tend to experience negative emotions, which in turn affects whether they stick with their treatment.\u003c\/p\u003e\n\n\u003cp\u003eDecision aids (DAs) were developed to address these gaps. They play a crucial role in enabling shared decision-making and improving decision quality. Decision aids do this by offering information on the available choices and their potential outcomes. Decision aids also clearly outline which decisions need to be made. Decision aids also help patients clarify their personal values and preferences. Formal evidence-based guidelines can supply professional medical knowledge and describe best clinical practice, but individual patient profiles also need to be taken into account.\u003c\/p\u003e\n\n\u003cp\u003eDecision aids have been widely used in other clinical areas. Decision aids have helped reduce bias toward hospice care among patients and families. Decision aids have clarified treatment preferences and values in type 2 diabetes. Decision aids have improved readiness to switch therapies among patients with rheumatoid arthritis who were not responding to their current treatment. In cancer care, the use of decision aids has grown notably. For example, decision aids help newly diagnosed breast cancer patients decide about mastectomy. Decision aids support young women with cancer in decisions about future fertility. Decision aids also help patients decide whether to join a cancer clinical trial.\u003c\/p\u003e\n\n\u003cp\u003eBut one outcome has stayed stubbornly inconsistent. Dr. Liao and colleagues found that decision aids had no significant effect on decision satisfaction among patients with hepatocellular cancer (liver cancer). Dr. Whelan and colleagues found that breast cancer patients in the decision aid group reported higher satisfaction with decision-making. Earlier meta-analyses mostly focused on a single cancer type, such as breast or prostate cancer. Few looked at the overall cancer population. That gap is exactly what this new review set out to fill.\u003c\/p\u003e\n\n\u003ch2 id=\"decision-aids\"\u003eWhat Exactly Is a Decision Aid?\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers define a decision aid as a tool that presents information on cancer-related options and the specific outcomes of each choice. The tool should help cancer patients make decisions based on their own values and preferences.\u003c\/p\u003e\n\n\u003cp\u003eDecision aids come in several common delivery formats:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBrochures\u003c\/strong\u003e — pamphlets and leaflets\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWeb-based tools\u003c\/strong\u003e — websites and online programs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMixed delivery methods\u003c\/strong\u003e — for example, an instructional video followed by a booklet, or a brochure paired with a structured PowerPoint presentation\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn this review, all three formats were tested separately in subgroup analyses. The researchers also recorded two technical quality features of each aid. The first was whether the aid reported outcome probabilities using absolute effect estimates. Absolute effect estimates are plain numbers such as \"3 in 100\" rather than confusing relative figures. The second was whether the aid communicated the certainty of the evidence to the user. The aid could do this, for example, using the GRADE system or a similar framework.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Researchers Conducted the Study\u003c\/h2\u003e\n\n\u003cp\u003eThis was a systematic review and meta-analysis, which means the researchers gathered every relevant study on the topic and combined their results statistically. The review was registered in advance with PROSPERO (registration number CRD42024519828), a public database that locks in a study's methods before the work begins. Results were reported according to the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), the standard checklist for this type of research.\u003c\/p\u003e\n\n\u003cp\u003eThe team searched eight databases and two search engines, from the beginning of each database up to November 30, 2025. The four English-language databases were Web of Science Core Collection, the Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). The four Chinese databases were China Biology Medicine disc (CBMdisc), China National Knowledge Infrastructure (CNKI), the VIP Database for Chinese Technical Periodicals, and WanFang Data. The two search engines were PubMed and Embase.\u003c\/p\u003e\n\n\u003cp\u003eSearch strategies followed Cochrane methodology and combined Medical Subject Heading (MeSH) terms, free-text words, and Boolean operators. Searches paired terms about cancer (such as \"cancer,\" \"tumor,\" \"carcinoma,\" \"oncology\") with terms about decision aids (such as \"decision support\" and \"shared decision-making\"). Only randomized controlled trials (RCTs) in human participants were included.\u003c\/p\u003e\n\n\u003cp\u003eStudies had to meet the PICOS criteria (Participants, Intervention, Comparison, Outcome, Study design):\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParticipants:\u003c\/strong\u003e adults aged 18 years or older, diagnosed with cancer, and facing a cancer-related clinical decision\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntervention:\u003c\/strong\u003e an experimental group using a decision aid\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComparison:\u003c\/strong\u003e usual care (standard care or therapies without a decision aid), including attention control conditions or a wait-list\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOutcomes:\u003c\/strong\u003e at least one of decision knowledge, decision conflict, or decision satisfaction, measured at any time after the decision-making encounter\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStudy design:\u003c\/strong\u003e clinical RCTs published in English\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe team excluded studies with inaccessible full text, as well as protocols, reviews, conference abstracts, quasi-experimental studies, case studies, and qualitative studies. Two reviewers (identified as YC and QWY) independently screened studies using EndNote 20 software. They then independently extracted data. Any disagreement about whether to include a study, or about the extracted data, was resolved by discussing it with a third author.\u003c\/p\u003e\n\n\u003cp\u003eThe extracted data covered four areas. The first area was study description: first author, year, and country. The second area was participant profile: mean age, cancer types, sample size, and gender. The third area was intervention and control group details: how the intervention worked, delivery method, and duration. The fourth area was outcome information: results, measurement tools, and assessment time. All data were stored in an Excel worksheet.\u003c\/p\u003e\n\n\u003cp\u003eStatistical analysis used Stata 16.0 software. For continuous outcomes, the researchers extracted the mean, standard deviation (SD), and sample size from each study to calculate an effect size. The researchers pooled results using the standardized mean difference. The standardized mean difference (SMD) is a way of comparing results across studies that used different measurement scales. The results were reported with 95% confidence intervals. Confidence intervals (CIs) are the range in which the true effect is likely to lie.\u003c\/p\u003e\n\n\u003cp\u003eAll meta-analyses used a random-effects model with the DerSimonian–Laird estimator. This model assumes the true effect may vary across studies because of differences in populations and interventions. Heterogeneity (how much the studies disagreed with each other) was measured with the I² statistic. An I² of 25% was considered low heterogeneity, 50% moderate, and 75% high. The random-effects model was used regardless of the I² value, but the degree of heterogeneity was reported and factored into how results were interpreted.\u003c\/p\u003e\n\n\u003cp\u003eFor trials comparing more than two groups that shared a common control group, the researchers split the control group into two roughly equal subgroups. This created independent comparisons and prevented the same participants from being counted twice.\u003c\/p\u003e\n\n\u003cp\u003eThree subgroup analyses were planned in advance, based on clinical reasoning:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDelivery method\u003c\/strong\u003e (brochure, web-based, or mixed). The hypothesis was that interactive and multimodal formats might drive greater engagement and knowledge retention than static materials.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer type\u003c\/strong\u003e (one specific cancer versus various types), because the decision context and treatment complexity differ substantially across cancers.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRegion\u003c\/strong\u003e where the decision aid was used, because cultural and healthcare system factors might change how acceptable and effective it is.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eTo test whether effects truly differed between subgroups, the researchers ran a formal interaction test. A p-value for interaction below 0.05 was considered statistically significant. The team stated clearly that these subgroup analyses were exploratory. They warned that statistical power within subgroups was limited and that multiple comparisons raise the risk of a type I error (finding a difference that is not real). The results could also be confounded by other study characteristics.\u003c\/p\u003e\n\n\u003cp\u003ePublication bias (the tendency for positive results to be published more often than negative ones) was assessed with funnel plots when at least 10 studies were available for an outcome. Egger's test was used, with a p-value below 0.05 taken as a signal of possible publication bias. When bias was indicated, the Duval and Tweedie trim-and-fill method was applied to estimate what the overall effect would look like after accounting for potentially missing studies. Sensitivity analysis was performed by removing individual studies from each forest plot to check how reliable the results were.\u003c\/p\u003e\n\n\u003ch2 id=\"study-characteristics\"\u003eWhat the 30 Included Studies Looked Like\u003c\/h2\u003e\n\n\u003cp\u003eThe initial search produced 26,307 records. After duplicates were removed and titles and abstracts were screened, 409 full-text reports were assessed for eligibility, and 30 randomized controlled trials met the criteria. Together they included 4,303 participants. A further 10 records were identified through citation searching.\u003c\/p\u003e\n\n\u003cp\u003eThe screening funnel shows how strict the criteria were. Of the records screened, 24,051 were excluded at the title and abstract stage. Of these, 18,238 were conference abstracts, proceedings, protocols, letters, replies, or commentaries. A further 3,906 were unrelated to the topic. The remaining 1,907 did not involve cancer patients. Of the 409 reports assessed in full, 379 were excluded. Of these, 27 were excluded because the data could not be used. 193 were excluded because the study type was incorrect. 125 were excluded because the outcomes did not include decision knowledge, decision conflict, or decision satisfaction. 34 were excluded because the population was not limited to cancer patients.\u003c\/p\u003e\n\n\u003cp\u003eIndividual study sample sizes ranged from 20 to 388 participants. The studies were published between 2001 and 2025. Twenty-nine used a two-arm RCT design. One study used three groups. One group received standard care. One group received standard care plus the Navya-PPT decision aid, followed by a research questionnaire completed by patients alone. One group received standard care plus the Navya-PPT, followed by the questionnaire completed with a key family member present.\u003c\/p\u003e\n\n\u003cp\u003eThe mean or median age of participants across studies ranged from 28.78 to 70.27 years. Geographically, 21 studies were conducted in Western countries and 9 in Asia.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnited States:\u003c\/strong\u003e 9 studies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCanada:\u003c\/strong\u003e 4 studies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnited Kingdom:\u003c\/strong\u003e 2 studies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNetherlands:\u003c\/strong\u003e 2 studies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSpain:\u003c\/strong\u003e 1 study\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSwitzerland:\u003c\/strong\u003e 1 study\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAustralia:\u003c\/strong\u003e 1 study\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGermany:\u003c\/strong\u003e 1 study\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChina:\u003c\/strong\u003e 4 studies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingapore, Malaysia, India, South Korea, Japan:\u003c\/strong\u003e 1 study each\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eSeven studies included people diagnosed with multiple types of cancer. The remaining 23 focused on a single cancer type:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBreast cancer:\u003c\/strong\u003e 14 studies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eProstate cancer:\u003c\/strong\u003e 4 studies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eColorectal cancer:\u003c\/strong\u003e 2 studies\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHepatocellular cancer:\u003c\/strong\u003e 1 study\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePapillary thyroid cancer:\u003c\/strong\u003e 1 study\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLung cancer:\u003c\/strong\u003e 1 study\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eControl group conditions also varied. In four studies, control participants received attention control. Attention control is an alternative intervention or contact of equal duration that did not contain the core elements of a decision aid. One example was browsing the National Cancer Institute's clinical trial informational website. In the other 26 studies, control participants received usual care throughout the study.\u003c\/p\u003e\n\n\u003ch2 id=\"measurement\"\u003eHow the Researchers Measured Results\u003c\/h2\u003e\n\n\u003cp\u003eThe measurement tools varied considerably across studies, which is one reason the researchers used standardized mean differences to pool the data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDecision knowledge\u003c\/strong\u003e was measured by the proportion of correct answers on a knowledge questionnaire. Thirteen distinct knowledge assessment tools were used. They evaluated comprehension across three domains:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDisease and treatment-specific facts\u003c\/strong\u003e — for example, understanding hepatocellular cancer treatment options or breast cancer surgery procedures\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRisk–benefit perceptions\u003c\/strong\u003e tied to different choices — for example, the probabilities of outcomes and side effects\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSystem or procedural knowledge\u003c\/strong\u003e — for example, health insurance concepts or advance care planning processes\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eMost of these tools were designed specifically for the individual study. Only one used a validated questionnaire. One study did not report which measurement tool it used.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDecision conflict\u003c\/strong\u003e was measured primarily with the 16-item Decision Conflict Scale (DCS), used in 22 studies. This scale assesses uncertainty, informed choice, value clarity, support, and perceived decision quality. One study supplemented the DCS with a brief 4-item screener. One study did not report the specific tool it used.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDecision satisfaction\u003c\/strong\u003e was measured with six different instruments. These focused on related but distinct constructs:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eGeneral satisfaction with the decision (Satisfaction With Decision Scale)\u003c\/li\u003e\n  \u003cli\u003eSatisfaction with the information received (Satisfaction With Cancer Information Profile)\u003c\/li\u003e\n  \u003cli\u003eSatisfaction with the decision-making process (Participation Satisfaction in Medical Decision-making Scale)\u003c\/li\u003e\n  \u003cli\u003eThe effective decision-making subscale\u003c\/li\u003e\n  \u003cli\u003eSatisfaction with clinical care\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"findings\"\u003eMain Findings: Knowledge Up, Conflict Down, Satisfaction Unchanged\u003c\/h2\u003e\n\n\u003cp\u003eThe pooled analysis showed a clear positive effect on decision knowledge. The standardized mean difference was \u003cstrong\u003e0.91\u003c\/strong\u003e, with a 95% confidence interval of \u003cstrong\u003e0.49 to 1.33\u003c\/strong\u003e. Because this interval does not cross zero, the finding is statistically significant. By conventional standards for the SMD (0.2 is small, 0.5 is moderate, and 0.8 is large), this is a large effect. In plain terms, patients who used a decision aid understood substantially more about their disease and treatment options than patients who received usual care.\u003c\/p\u003e\n\n\u003cp\u003eThe analysis also showed a reduction in decision conflict. The standardized mean difference was \u003cstrong\u003e−0.23\u003c\/strong\u003e, with a 95% confidence interval of \u003cstrong\u003e−0.39 to −0.07\u003c\/strong\u003e. The negative direction means conflict went down, and because the interval stays below zero, the result is statistically significant. The size of the benefit was modest rather than large. Patients using decision aids felt somewhat less uncertain and torn about their choices.\u003c\/p\u003e\n\n\u003cp\u003eDecision satisfaction, however, showed no significant effect. The standardized mean difference was \u003cstrong\u003e0.03\u003c\/strong\u003e, with a wide 95% confidence interval of \u003cstrong\u003e−0.42 to 0.48\u003c\/strong\u003e. Because that interval crosses zero, the researchers could not conclude that decision aids changed satisfaction either way. The width of the interval also signals imprecision — in other words, the studies did not agree closely enough for a confident answer.\u003c\/p\u003e\n\n\u003cp\u003eThe certainty of the evidence differed by outcome when judged with the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation):\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDecision knowledge:\u003c\/strong\u003e low certainty of evidence\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDecision conflict:\u003c\/strong\u003e moderate certainty of evidence\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDecision satisfaction:\u003c\/strong\u003e moderate certainty of evidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"subgroups\"\u003eSubgroup Findings: Which Formats Work Best\u003c\/h2\u003e\n\n\u003cp\u003eWhen the researchers separated studies by how the decision aid was delivered, a pattern emerged. All three delivery methods — brochure, web-based, and mixed — were associated with increased decision knowledge. However, only the web-based and mixed methods were associated with reduced decision conflict.\u003c\/p\u003e\n\n\u003cp\u003eThat difference matters. It suggests that simply handing a patient a pamphlet can improve what they know, but may not do much to ease the emotional uncertainty they feel. Interactive and combined formats appear to do both.\u003c\/p\u003e\n\n\u003cp\u003eA second pattern appeared when studies were grouped by whether the decision aid targeted one specific cancer type or multiple cancer types. Decision aids designed for both specific and various cancer types improved knowledge. But only those targeting a specific cancer type were associated with reduced decision conflict. In other words, tailoring the tool to a particular disease and its particular trade-offs seems to help with the emotional side of deciding.\u003c\/p\u003e\n\n\u003cp\u003eThe researchers also examined the region where decision aids were conducted, noting that cultural and healthcare system factors might change how acceptable and effective these tools are. They treated all subgroup findings as exploratory, and they advised caution because within-subgroup statistical power was limited and multiple comparisons increase the chance of a false positive.\u003c\/p\u003e\n\n\u003ch2 id=\"bias\"\u003eRisk of Bias and Certainty of the Evidence\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers assessed each study using the Cochrane Risk of Bias tool version 2.0 (ROB 2), which examines five domains: the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported results. Some studies reported an intention-to-treat analysis, analyzing all participants as originally assigned. For these studies, the team assessed the \"effect of assignment to the intervention.\" Other studies reported a per-protocol analysis, analyzing only those who completed treatment as planned. For these studies, the team assessed the \"effect of adhering to the intervention.\" Each domain was rated as low risk of bias, some concerns, or high risk of bias.\u003c\/p\u003e\n\n\u003cp\u003eOne domain stood out. \"Selection of the reporting results\" raised frequent concerns. A total of 13 studies were judged to have some concerns in this domain. This was typically because the trial protocol or registration record did not contain enough information to confidently rule out selective reporting. In contrast, the \"randomization process\" and \"deviations from the intended interventions\" domains were most often judged as low risk. Only a small number of studies were rated as having some concerns (two and six studies, respectively) or high risk (four and one studies, respectively) in these areas.\u003c\/p\u003e\n\n\u003cp\u003eOn publication bias, the researchers reported that Egger's test for decision conflict did not show significant evidence of bias. Funnel plots were generated only when at least 10 studies were available for an outcome. The trim-and-fill method was applied when bias was indicated. This estimated the effect after accounting for potentially missing studies. Sensitivity analyses were also run by removing individual studies from each forest plot to test how reliable the results were.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe practical message is straightforward. If you are facing a cancer treatment decision, a decision aid is likely to help you understand your options better. A decision aid may also help you feel less conflicted about the choice. That is a meaningful benefit, because research shows that patients with inadequate decision knowledge often experience negative emotions that can interfere with sticking to treatment.\u003c\/p\u003e\n\n\u003cp\u003eWhat a decision aid probably will not do, based on this evidence, is make you feel satisfied with your decision. That is an important distinction. Satisfaction appears to depend on factors beyond information alone. The researchers note that decision aids need to be tailored based on cancer type, educational level, and health literacy to address unmet needs in decision satisfaction.\u003c\/p\u003e\n\n\u003cp\u003eAsk your care team specifically whether a decision aid exists for your cancer type and your decision. If a web-based or mixed-format tool is available, the evidence suggests it is more likely to reduce your sense of conflict than a brochure alone.\u003c\/p\u003e\n\n\u003ch2 id=\"nursing\"\u003eWhat This Means for Nurses and Health Systems\u003c\/h2\u003e\n\n\u003cp\u003eThe authors state their nursing management implications directly. Nurses should integrate evidence-based decision aids into routine cancer care, particularly web-based and mixed delivery formats, to enhance patients' decision knowledge and reduce conflict.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also emphasize tailoring. To maximize effectiveness, decision aids should be adapted based on targeted cancer types, educational levels, and health literacy, so they can address the unmet needs that remain in decision satisfaction.\u003c\/p\u003e\n\n\u003cp\u003eNurses are well positioned here. The review notes that patients often hesitate to ask questions because they fear negative reactions, feel confused by medical terminology, or believe nurses and doctors are too busy. A well-designed decision aid can carry part of that information load, freeing the clinical conversation for the patient's values and concerns.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Study Could Not Prove\u003c\/h2\u003e\n\n\u003cp\u003eSeveral limitations deserve attention, and the authors flag most of them themselves.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSubgroup results are exploratory.\u003c\/strong\u003e The delivery-method and cancer-type findings come from exploratory analyses with limited statistical power within subgroups. Multiple comparisons also raise the risk of a type I error, meaning some apparent differences could be chance findings. The authors caution that these results are observational in nature and may be confounded by other study characteristics.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMeasurement tools varied widely.\u003c\/strong\u003e Thirteen different knowledge tools, one 16-item conflict scale (sometimes supplemented), and six satisfaction instruments were used. Standardized mean differences allow pooling across different scales, but they do not eliminate the underlying inconsistency. Most knowledge tools were study-specific rather than validated, and two studies did not report their measurement tool at all.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCertainty of evidence was limited.\u003c\/strong\u003e GRADE rated the evidence for decision knowledge as low certainty, and for decision conflict and decision satisfaction as moderate. For imprecision, the researchers defined a minimal important difference (MID) of 10 points in advance for outcomes measured on a 0–100 scale, and downgraded evidence when the confidence interval crossed that threshold.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe satisfaction result is imprecise.\u003c\/strong\u003e The confidence interval for decision satisfaction ranged from −0.42 to 0.48 and crossed zero. The honest conclusion is that the studies do not provide a clear answer either way — not that decision aids are definitely useless for satisfaction.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eReporting concerns were common.\u003c\/strong\u003e Thirteen studies had some concerns about selective reporting because their protocols or registrations lacked enough detail.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCancer types were unevenly represented.\u003c\/strong\u003e Breast cancer dominated with 14 of 23 single-cancer studies, followed by prostate cancer with 4. Colorectal, hepatocellular, papillary thyroid, and lung cancer were represented by just one or two studies each.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003ePractical Recommendations\u003c\/h2\u003e\n\n\u003cp\u003eBased on what this review found, here is how patients, families, and clinicians can act on the evidence:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk whether a decision aid exists for your decision.\u003c\/strong\u003e Ask your oncology team or nurse whether there is a decision aid for your cancer type and the specific choice you face.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrefer web-based or mixed formats when available.\u003c\/strong\u003e All three formats improved knowledge, but only web-based and mixed methods also reduced decision conflict in the subgroup analysis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLook for tools tailored to your cancer type.\u003c\/strong\u003e Only decision aids targeting a specific cancer type were linked to reduced decision conflict.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect better understanding, not automatic satisfaction.\u003c\/strong\u003e Decision aids reliably improve knowledge and modestly reduce conflict, but they did not significantly improve satisfaction in this pooled analysis. Tell your team if your concerns remain unaddressed.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCheck that the aid gives absolute numbers.\u003c\/strong\u003e The review recorded whether each aid reported outcome probabilities using absolute effect estimates, which are easier to understand than relative figures.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUse the aid alongside, not instead of, a conversation.\u003c\/strong\u003e Decision aids are designed to prepare patients to participate actively in shared decision-making with their clinicians.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe bottom line: decision aids work well for understanding and modestly well for easing uncertainty. Improving satisfaction will likely require more tailoring to individual patients and their circumstances.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is a decision aid for cancer treatment?\u003c\/h3\u003e\n\u003cp\u003eA decision aid is a structured tool that presents information on cancer-related options and the specific outcomes of each choice. It helps patients make decisions based on their own values and preferences. Decision aids come as brochures, web-based tools, or mixed formats, such as a video followed by a booklet. They are designed to support shared decision-making with your care team.\u003c\/p\u003e\n\u003ch3\u003eWill a decision aid help me understand my cancer treatment options?\u003c\/h3\u003e\n\u003cp\u003eIn a review of 30 randomized trials involving 4,303 cancer patients, decision aids clearly improved decision knowledge, with a large effect. Patients who used a decision aid understood substantially more about their disease and treatment options than those who received usual care. Brochure, web-based, and mixed formats all improved knowledge. The certainty of this evidence was rated low.\u003c\/p\u003e\n\u003ch3\u003eCan a decision aid reduce the uncertainty I feel about choosing treatment?\u003c\/h3\u003e\n\u003cp\u003eIn the same review of 30 trials with 4,303 patients, decision aids modestly reduced decision conflict, the distressing uncertainty felt when facing hard choices. The effect was statistically significant but modest rather than large. Only web-based and mixed-format aids, and aids tailored to one specific cancer type, were linked to reduced conflict. The certainty of this evidence was rated moderate.\u003c\/p\u003e\n\u003ch3\u003eWill using a decision aid make me feel satisfied with my treatment decision?\u003c\/h3\u003e\n\u003cp\u003eIn the pooled analysis of 30 trials with 4,303 patients, decision aids did not significantly improve decision satisfaction. The result was imprecise, meaning the studies did not agree closely enough for a confident answer either way. Satisfaction appears to depend on factors beyond information alone. The researchers suggest decision aids need tailoring by cancer type, educational level, and health literacy.\u003c\/p\u003e\n\u003ch3\u003eWhich format of decision aid should I ask for?\u003c\/h3\u003e\n\u003cp\u003eIn subgroup analyses of 30 trials, all three formats improved knowledge, but only web-based and mixed methods also reduced decision conflict. Brochure-only aids improved knowledge but not conflict. Aids targeting a specific cancer type were linked to reduced conflict, while those covering various cancer types were not. These subgroup findings were exploratory, with limited statistical power.\u003c\/p\u003e\n\u003ch3\u003eDoes a decision aid replace talking with my cancer team?\u003c\/h3\u003e\n\u003cp\u003eNo. Decision aids are designed to prepare patients to participate actively in shared decision-making with their clinicians, so they should be used alongside, not instead of, a conversation. The review notes patients often hesitate to ask questions because they fear negative reactions, feel confused by medical terminology, or believe nurses and doctors are too busy. An aid can carry part of that information load.\u003c\/p\u003e\n\u003ch3\u003eWhat are the limitations of the evidence on decision aids for cancer patients?\u003c\/h3\u003e\n\u003cp\u003eThe review of 30 trials with 4,303 patients had limitations. Subgroup findings were exploratory with limited statistical power. Measurement tools varied widely, and most knowledge tools were study-specific rather than validated. Certainty of evidence was low for knowledge and moderate for conflict and satisfaction. Thirteen studies raised concerns about selective reporting. Breast cancer dominated, with 14 of 23 single-cancer studies.\u003c\/p\u003e\n\u003ch3\u003eWhen should a patient facing a cancer treatment decision seek a second opinion?\u003c\/h3\u003e\n\u003cp\u003eCancer decisions are preference-sensitive. Decision aids improve knowledge and modestly reduce conflict, but they do not reliably improve satisfaction. A second opinion can help when options remain unclear or your values feel unaddressed. Seek a second opinion if you are unsure which treatment fits your circumstances. Seek one if your cancer type is not well represented in the evidence. Seek one if you want your pathology and imaging reviewed before committing. A second opinion is meant to work alongside, not replace, shared decision-making with your care team. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Effects of Decision Aids on Decision Knowledge, Conflict, and Satisfaction Among Patients With Cancer: A Systematic Review and Meta-Analysis.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Yang Chen, Chuanmei Zhu, Linna Li, Juejin Li, Qianwen Yan, and Xiaolin Hu\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e West China School of Nursing, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Outpatient Department, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Alice Lee Centre for Nursing Studies, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Tianfu Jincheng Laboratory, City of Future Medicine, Chengdu, Sichuan, China\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Journal of Nursing Management, 2026; volume 2026, article 6436400. DOI: 10.1155\/jonm\/6436400. Open access under a Creative Commons Attribution License.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegistration:\u003c\/strong\u003e PROSPERO CRD42024519828\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576775983260,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/de\/products\/do-decision-aids-actually-help-cancer-patients-decide-what-30-studies-and-4-303-patients-show","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}